Nuformix (FRA:1RT) YoY EBITDA Growth: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nuformix YoY EBITDA Growth?

Nuformix FRA:1RT YoY EBITDA Growth is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Nuformix's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 0.00%.

Nuformix's EBITDA per Share for the six months ended in Mar. 2026 was €0.00.

Nuformix YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Nuformix's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix YoY EBITDA Growth Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.00 33.33 50.00 0.00 100.00

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 100.00 0.00 0.00 0.00

Nuformix YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Nuformix's YoY EBITDA Growth for the fiscal year that ended in Sep. 2025 is calculated as:

YoY EBITDA Growth (A: Sep. 2025 )
=(EBITDA per Share (A: Sep. 2025 )-EBITDA per Share (A: Sep. 2024 ))/ | EBITDA per Share (A: Sep. 2024 ) |
=(-0--0.001)/ | -0.001 |
=100.00 %

Nuformix's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0--0)/ | -0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Nuformix (FRA:1RT) has a YoY EBITDA Growth of 0.00% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Nuformix and its competitors.
Is Nuformix's YoY EBITDA Growth too high?
Nuformix's current YoY EBITDA Growth is 0.00%.
How does Nuformix's YoY EBITDA Growth compare to VRTX and REGN?
Nuformix's YoY EBITDA Growth of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Nuformix and its competitors. Nuformix's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (FRA:1RT) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Nuformix (FRA:1RT), the current YoY EBITDA Growth is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges NFX:UK1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.